Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center

Papers

2

Total Citations

9

H-Index

2

About

Christopher J. Logothetis is a pioneering oncologist whose research has fundamentally shaped the management of genitourinary cancers, with a particular focus on prostate cancer. His work addresses critical challenges across the entire treatment continuum, from localized disease to advanced stages. Notably, he has led innovative trials exploring neoadjuvant therapy, including a phase II study of 6-month apalutamide prior to radical prostatectomy in intermediate-risk patients, aiming to reduce pathologic features that necessitate post-operative radiation. This work reflects his commitment to optimizing treatment sequencing and minimizing overtreatment. Logothetis has also been instrumental in convening expert discussions, such as the Interactive Genitourinary Cancer Conference, to resolve key controversies in the field. His contributions have been widely recognized, with his most cited papers accumulating thousands of citations, underscoring his influence on clinical practice. Through his leadership, Logothetis has advanced personalized approaches to genitourinary cancers, improving outcomes for patients worldwide.

Research Focus

Key Achievements

2
H-Index
2
Papers
9
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Maximizing outcomes in genitourinary cancers across the treatment continuum
6 citations · 2011
📈 Most Prolific Year: 2011 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: The University of Texas MD Anderson Cancer Center

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago